Clinical Trial

Drug-Interaction Assessment of GSK3772701 in Healthy Male and Female Participants Aged 18 to 55 Years

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study aims to evaluate whether GSK3772701 alters the pharmacokinetics (PK) of midazolam (MDZ), a standard probe substrate for the CYP3A4 enzyme. The findings are planned to be used to determine whether GSK3772701 acts as an inducer and/or inhibitor of CYP3A4 and will help guide recommendations for safe co-administration with CYP3A4 substrates.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-22
Trial Details
NCT Number NCT07670377
Lead Sponsor GlaxoSmithKline
Conditions Malaria, Falciparum
Enrollment 20 participants
Start Date 2026-06-26
Primary Completion 2026-08-24 (estimated)
Study Completion 2026-08-24 (estimated)
Updated on ClinicalTrials.gov 2026-07-21